Plain-English translation of NCT06990269 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing a medication called to see if it can slow or stop geographic atrophy, a condition where the light-sensitive tissue in the back of the eye gradually breaks down and causes vision loss. Researchers will compare the medication to a placebo (a saline injection with no active ingredient) to understand whether the treatment works and is safe. About 240 people with this specific type of age-related macular degeneration will participate.
Currently, there are limited treatment options for geographic atrophy, and vision loss from this condition can significantly impact quality of life. This trial is testing whether this new medication can help protect remaining vision or slow the progression of the disease.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to receive either the new medication or a placebo injection under the skin. You'll visit the clinic regularly for injections and to have your eyes examined with imaging scans to track whether your vision is staying stable or changing. The study will monitor your safety throughout and collect information about how the medication works in your body.
AI-generated summary from trial data · Jun 21, 2026 · Not medical advice
United States